NK- and T-cell lymphoma - historical
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NKTCL page for current regimens.
| Last updated on 2024-07-23: 1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Pembrolizumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Kwong et al. 2017 | Not reported | Case series |
Note: prospective trials are underway.
References
- Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed